• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines

Research Brief on 3-(oxolan-2-yl)pyrrolidine (CAS: 1430091-80-7) in Chemical Biology and Pharmaceutical Applications

The compound 3-(oxolan-2-yl)pyrrolidine (CAS: 1430091-80-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This heterocyclic compound, featuring a pyrrolidine ring fused with a tetrahydrofuran (oxolane) moiety, serves as a versatile scaffold for drug discovery. Recent studies highlight its role as a key intermediate in the synthesis of bioactive molecules targeting neurological disorders, infectious diseases, and cancer.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility as a building block for sigma-1 receptor ligands, which show promise in treating neuropathic pain and neurodegenerative diseases. The researchers utilized 3-(oxolan-2-yl)pyrrolidine as a core structure, modifying its side chains to enhance binding affinity and selectivity. Molecular docking simulations revealed that the oxolane ring contributes to optimal spatial orientation for receptor interaction, while the pyrrolidine nitrogen facilitates hydrogen bonding with key amino acid residues.

In antimicrobial research, a team from the University of Cambridge reported in Bioorganic & Medicinal Chemistry Letters (2024) that derivatives of 1430091-80-7 exhibited potent activity against drug-resistant Gram-positive bacteria, including MRSA. The study identified that the compound's ability to disrupt bacterial cell wall synthesis stems from its interaction with penicillin-binding proteins (PBPs), with the oxolane-pyrrolidine hybrid structure playing a crucial role in bypassing common resistance mechanisms.

From a synthetic chemistry perspective, advances in the asymmetric synthesis of 3-(oxolan-2-yl)pyrrolidine have been achieved using organocatalytic methods. A Nature Communications paper (2023) described an enantioselective [3+2] cycloaddition strategy that yields the compound with >99% ee, addressing previous challenges in obtaining optically pure forms for chiral drug development. This methodological breakthrough has significant implications for producing stereospecific derivatives with improved pharmacological profiles.

Ongoing clinical investigations focus on the compound's potential as a CNS-penetrant agent. Preliminary pharmacokinetic studies in animal models show favorable blood-brain barrier penetration, attributed to the molecule's balanced lipophilicity (calculated logP 1.2) and molecular weight (141.17 g/mol). However, metabolic stability remains an area for optimization, as first-pass metabolism studies indicate rapid oxidation of the pyrrolidine ring in some derivatives.

The commercial availability of 3-(oxolan-2-yl)pyrrolidine through major chemical suppliers (e.g., Sigma-Aldrich, TCI Chemicals) under CAS 1430091-80-7 has facilitated broader research adoption. Current price benchmarks range from $120-$250 per gram at research quantities, reflecting both the compound's synthetic complexity and growing demand. Patent analysis shows increasing IP activity, with 14 new applications filed in 2023-2024 covering novel derivatives and synthetic methods.

Future research directions likely include structure-activity relationship (SAR) studies to optimize the scaffold's therapeutic index, particularly for oncology targets where preliminary data shows inhibition of protein-protein interactions involved in tumor progression. The compound's versatility as a synthetic intermediate suggests it will remain a focus of medicinal chemistry efforts in developing next-generation small molecule therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)